BWAY News and Press, BrainsWay Ltd. From 04/29/21

BrainsWay (BWAY) announces the distribution of its first 10 Deep Transcranial Magnetic Stimulation ((Deep TMS)) devices for smoking addiction to practices across the United States.Deep TMS is the first FDA-cleared noninvasive treatment in the addiction space for any TMS device, and ...

CRESSKILL, N.J. and JERUSALEM, April 29, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive treatment of brain disorders, today announced the distribution of its first...

BrainsWay (BWAY) announces that the U.S. FDA has granted 501k clearance for the company’s Theta Burst three-minute protocol utilizing its proprietary Deep Transcranial Magnetic Stimulation ((Deep TMS)) system for the treatment of major depressive disorder ((MDD)).The BrainsWay Theta Bu...

CRESSKILL, N.J. and JERUSALEM, April 26, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U....

CRESSKILL, N.J. and JERUSALEM, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced today tha...

BrainsWay Ltd. (BWAY) Q4 2020 Earnings Conference Call March 25, 2021 8:30 AM ET Company Participants Chase Oswald – LifeSci Advisors Christopher von Jako – President and Chief Executive Officer Hadar Levy – Senior Vice President and General Manager-North America and Inte...

Brainsway (BWAY): Q4 GAAP EPS of -$0.02 beats by $0.03.Revenue of $7.07M (+12.4% Y/Y) beats by $0.13M.Cash, cash equivalents and short-term deposits as of December 31, 2020 amounted to $17.2 million, compared with $16.0 million at the end of the previous quarter, reflecting positive cash flow...

CRESSKILL, N.J. and JERUSALEM, March 24, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth quart...

CRESSKILL, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its fourth quarter and full ...

CRESSKILL, N.J. and JERUSALEM, March 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D.,...